Form 4 for TNXP Tonix Pharmaceuticals Holding Corp.
Accepted 2025-02-27 00:00:00 ET · period of report 2025-02-05 · accession 0001839882-25-011955 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-27 | 2025-02-05 | TNXP | SULLIVAN GREGORY M | Chief Medical Off | J - Other | $1.47 | -0.11 | 0 | -100% | -$0.16 |
| DM | 2025-02-27 | 2025-02-25 | TNXP | SULLIVAN GREGORY M | Chief Medical Off | A - Grant | $0.00 | +58.0K | 29.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.001 | 2025-02-05 | J | D | 0.11 | $1.47 | 0 | D | — | — | |
| 2 | Derivative | Stock Option | 2025-02-25 | A | A | 29,017 | $0.00 | 29,017 | D | $8.05 · 2026-02-25 to 2035-02-25 | 29,017 Common Stock | (F3) The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. (F2) One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. |
| 3 | Derivative | Stock Option | 2025-02-25 | A | A | 29,017 | $0.00 | 29,017 | D | $10.06 · 2026-02-25 to 2035-02-25 | 29,017 Common Stock | (F3) The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. (F2) One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. |